How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy:the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark by Polzik, Peter et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
How biomarkers reflect the prognosis and treatment of necrotising soft tissue
infections and the effects of hyperbaric oxygen therapy
Polzik, Peter; Johansson, Pär I; Hyldegaard, Ole
Published in:
B M J Open
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Polzik, P., Johansson, P. I., & Hyldegaard, O. (2017). How biomarkers reflect the prognosis and treatment of
necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective
cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark. B M J Open, 7(10),
[e017805].
Download date: 03. Feb. 2020
 1Polzik P, et al. BMJ Open 2017;7:e017805. doi:10.1136/bmjopen-2017-017805
Open Access 
 AbstrAct
Introduction Not enough is known regarding the 
prognosis and treatment of necrotising soft tissue 
infections (NSTIs). Mortality has been shown to be 
25%–35%, with survivors coping with amputations and 
prolonged rehabilitation. This study will evaluate soluble 
urokinase-type plasminogen activator receptor (suPAR) 
as a possible prognostic marker of NSTI severity and 
mortality, as well as whether hyperbaric oxygen therapy 
(HBOT) can modulate markers of endothelial damage 
during NSTI. We hypothesise that in patients with NSTI, 
suPAR can provide prognostic risk assessment on hospital 
admission and that HBOT can reduce the endothelial 
damage that these patients are exposed to.
Methods and analysis This is a prospective observational 
study. Biomarkers will be measured in 150 patients who 
have been diagnosed with NSTI. On admission, baseline 
blood samples will be obtained. Following surgery and 
HBOT, daily blood samples will be obtained in order to 
measure endothelial and prognostic biomarkers (soluble 
thrombomodulin, syndecan-1, sE-selectin, vascular 
endothelial (VE)-cadherin, protein C and suPAR levels). 
Clinical data will be acquired during the first 7 days of stay 
in the intensive care unit. The primary outcomes in studies 
I and II will be endothelial biomarker levels after HBOT, and 
in study III suPAR levels as a marker of disease prognosis 
and severity.
Ethics and dissemination The study has been 
approved by the Regional Scientific Ethical Committee of 
Copenhagen (H-16021845) and the Danish Data Protection 
Agency (RH-2016-199). Results will be presented at 
national and international conferences and published in 
peer-reviewed scientific journals.
trial registration number  ClinicalTrials. gov Identifier 
NCT03147352. (Pre-results)
IntroductIon
Necrotising soft tissue infections (NSTIs) are 
serious and deadly. They are characterised by 
rapidly progressing soft-tissue inflammation 
with necrosis and can quickly cause multiple 
organ failure and death. They have a wide 
range of presentations. Patients can become 
mortally infected in hours. Mortality has been 
shown to be 25%–35%, with survivors coping 
with amputations and prolonged rehabilita-
tion.1 Septic shock accompanies death due to 
NSTI.
Currently, we lack the proper tools to eval-
uate the severity and prognosis of NSTI in 
individual patients. This results in necessary, 
yet sometimes overzealous surgical debride-
ment, culminating in prolonged patient 
rehabilitation and amputations. Hyperbaric 
oxygen therapy (HBOT) may be added as 
adjunctive therapy of NSTI.2–4 Large database 
surveys indicate that HBOT improves survival 
of patients with NSTI in hospitals capable 
of providing HBOT—the effect being most 
prominent for severely ill patients, with 
septic shock.2–4 Large randomised controlled 
trials (RCTs) are lacking, in large part due 
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Protocol
strengths and limitations of this study
 ► It is the largest, single-centre prospective cohort 
study of biomarkers during necrotising soft tissue 
infections (NSTIs).
 ► The study will measure biomarkers never previously 
examined in patients with NSTI.
 ► The study’s outcomes may provide valuable 
evidence for future studies of optimisation of NSTI 
prognosis and treatment.
 ► Due to the non-randomised design, we may be 
subject to biases due to differences in hyperbaric 
oxygen therapy allocation and result interpretation.
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to ethical concerns. However, in the present prospective 
cohort, HBOT is already being used as part of the stan-
dard NSTI treatment in a multidisciplinary setting in a 
tertiary hospital, with centralised treatment expertise and 
an in-hospital HBOT unit. We wish to use this unique 
opportunity to examine the effects of HBOT during NSTI 
by means of biomarkers, in order to obtain pathophysio-
logical knowledge about the effects of HBOT. The data 
will also contribute to improved decision-making with 
respect to the proper design and ethical justification of 
future RCT studies on the effects of HBOT.
Accordingly, our first and second study will analyse 
markers of endothelial function in order to examine the 
effect of HBOT on patients with NSTI. Our third study 
will look at the prognostic value of soluble urokinase-type 
plasminogen activator receptor (suPAR) in NSTI. SuPAR 
is a biomarker reflecting immune system activity.5
studies I and II: endothelial function during nstI and the 
effects of Hbot
Endothelial dysfunction during sepsis is the result of 
damage to the endothelial glycocalyx, which leads to 
platelet aggregation, leucocyte adhesion and an increase 
in endothelial permeability. The result is capillary leakage 
and tissue oedema. At the same time, the patients’ blood 
is anticoagulated endogenously. This capillary leakage 
and anticoagulation ultimately lead to intravascular 
volume depletion.6–9 Tissue dysfunction is due to inflam-
mation, reduced tissue blood flow and ischaemia, which 
can lead to multiorgan failure and death.6–9 Recently, we 
have demonstrated in more than 4400 patients with acute 
critical illness (sepsis,10–12 trauma,13 myocardial infarc-
tion14 and resuscitated cardiac arrest15) that endothelial 
breakdown as evaluated by the biomarkers soluble throm-
bomodulin (sTM) and syndecan-1 is independently asso-
ciated with development of multiorgan failure and death. 
We are interested in examining whether this also is the 
case with NSTIs, since most of these patients are also 
septic. sTM and syndecan-1 have been shown as markers of 
endothelial and glycocalyx damage, respectively.16 17 sTM 
is released from endothelial cells on damage, while 
damage to the glycocalyx releases syndecan-1. Increases 
in these markers therefore correspond to increased levels 
of endothelial damage.18
In septic rats, HBOT has been shown to attenuate levels 
of proinflammatory cytokines and prevent coagulation 
disorders.19–22 Furthermore, HBOT may improve micro-
circulation by inducing the formation of reactive oxygen 
species23 24 and decreasing the adherence of polymor-
phonuclear neutrophils to the endothelial cell wall,25–28 
possibly by downregulation of intracellular adhesion 
molecule-1.29 30 sE-Selectin and vascular endothelial 
(VE)-cadherin are markers of leucocyte adhesion and 
endothelial barrier function, respectively.31 32 sE-Selectin 
is responsible for interactions between leucocytes and the 
endothelium, and increased expression is due to endo-
thelial activation.33 Lower concentrations of VE-cadherin 
result in loss of vascular integrity.34 
We believe it is plausible to consider the potential bene-
ficial effects of HBOT on patients with NSTI in septic 
shock due to HBOT mediating an endothelial/glycoc-
alyx protective effect, which enhances the endothelial 
integrity with its effects on coagulation and platelet reac-
tivity and functionality.26–30 Also, HBOT has been shown 
to induce a cytoprotective and angiogenic response in 
human endothelial cells.35 A deeper understanding of 
endothelial dysfunction during NSTI, and the possible 
countering effect of HBOT, could contribute to a better 
understanding of this disease.
Therefore, the purpose of studies I and II will be to 
investigate the effect of HBOT on possible endothelial 
dysfunction in patients with NSTI. We will do this by 
measuring sTM and syndecan-1 in study I, as well as sE-Se-
lectin, VE-cadherin and protein C in study II.
study III: suPAr as a prognostic biomarker for nstI
suPAR receptor has been shown to predict the risk of 
developing a wide range of chronic conditions, as well as 
predicting mortality during acute infectious conditions. 
The risk of developing cardiovascular disease, diabetes 
mellitus, cancer,36 37 acute exacerbation of chronic obstruc-
tive lung disease,38 mortality during bacteraemia,39–41 
mortality during bacterial meningitis,42 mortality from 
systemic inflammatory response syndrome43 as well as 
negative prognosis during sepsis44 are all correlated 
with higher than normal levels of suPAR. Likewise, since 
NSTIs are also infectious diseases, we are interested in 
examining suPARs potential during NSTIs.
In our third study, we will assess suPARs possible value 
as a prognostic biomarker for mortality and morbidity as 
well as clinical condition during NSTI.
MEtHods And AnAlysIs
study design
The PROTREAT study is a prospective observational 
substudy of the INFECT project ( ClinicalTrials. gov Iden-
tifier: NCT01790698). The INFECT project involves five 
centres (Copenhagen University Hospital, Karolinska 
Institute, Blekinge Hospital, Sahlgrenska Hospital, 
University Hospital of Bergen) with the objective of 
improving the outcome in patients with NSTI.
The PROTREAT study will be conducted at Copen-
hagen University Hospital and Hvidovre Hospital. The 
study will use data gathered in Denmark on patients 
diagnosed with NSTI, who are admitted to Copenhagen 
University Hospital. The patients are enrolled immedi-
ately on diagnosis using predefined criteria for NSTI, 
as specified below. The first patient was enrolled on 
26 February 2013 and inclusion is ongoing. Due to the 
low incidence of NSTI, the enrolment period of this study 
will extend over 4.5 years, with expected closure by the 
end of August 2017.
For study III, only the patient with NSTI cohort will be 
used. For studies I and II, we will also use data gathered 
from a group of 65 elective orthopaedic surgery patients, 
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Table 1 Overview of blood sampling procedures
Day 0 (time of admission) Day 1 Day 2 Day 3
Patients with NSTI Patients with NSTI Patients with NSTI Patients with NSTI
EDTA blood
(two collection tubes)
EDTA blood
(two collection tubes)
EDTA blood
(two collection tubes)
EDTA blood
(two collection tubes)
NSTI, necrotising soft tissue infection.
Table 2 Baseline characteristics and clinical data
Data Description
Baseline 
characteristics
 ►  Sex and age
 –  ComorbiditiesDiabetes mellitus, cirrhosis of the liver, renal disease, heart disease, vascular disease, 
hepatitis, intravenous drug abuse, history of cancer, COPD, immunosuppression
 ►  Body mass index
 ►  Primary infection site
 –  Origin of infection Chronic wound, injection, boil/furuncle, animal bite, idiopathic, trauma, postoperative 
infection, perianal abscess, other
 –  Symptoms registered at the primary hospital Oedema, erythema, tachycardia, fever, bullae
 ►  Responsible micro-organism
 ►  Time between admission to primary hospital and first debridement
 ►  Time between admission to primary hospital and admission to ICU
 ►  Steroid treatment (injection/oral) prior to development of NSTI (Time frame: up to 7 days prior to surgical 
diagnosis at primary hospital)
 ►  Other medication
Clinical data 
from the ICU
 ►MAP (mm Hg)
 ►  Heart rate (bpm)
 ►  Arterial blood gas values: pO2, pCO2, HCO3−, base excess, pH
 ►  K+, Na+, Ca2+, glucose, creatinine, haemoglobin, haematocrit
 ►  Norepinephrine infusion
 ►  Ventilator treatment
 ►  Vasopressor treatment
 ►  Renal replacement treatment
 ►  LRINEC score
bpm, beats per minute; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; LRINEC, Laboratory Risk Indicator for 
Necrotising Fasciitis; MAP, mean arterial blood pressure; NSTI, necrotising soft tissue infection; pO2, partial pressure of oxygen; pCO2, partial 
pressure of carbon dioxide.
functioning as controls for our patients with NSTI. 
Furthermore, data on endothelial function from the 
Scandinavian Starch for Severe Sepsis/Septic Shock trial 
( ClinicalTrials. gov: NCT00962156) of patients with sepsis 
will be used to illustrate and compare with the modula-
tion of endothelial function in patients with sepsis who 
do not receive HBOT.
Inclusion and exclusion criteria
Studies I, II and III: patients with NSTI
Patient inclusion criteria are (all of which must be met):
1. Diagnosed with NSTI based on surgical findings 
(necrosis of any soft tissue compartment; dermis, 
hypodermis, fascia or muscle)
2. Age ≥18 years
3. Admitted to the intensive care unit (ICU) and/or 
operated for NSTI at Copenhagen University Hospital.
Patient exclusion criteria are:
1. They are categorised as non-NSTI in the operating 
theatre.
Studies I and II: orthopaedic control patients
Control patient inclusion criteria are (all of which must 
be met):
1. Undergoing elective orthopaedic surgery (non-
pathological fractures, joint replacement surgery or 
spine surgery) at Copenhagen University Hospital
2. Age ≥18 years.
Patient exclusion criteria are:
1. Ongoing infection or inflammatory condition.
data collection
A blood sample taken from an arterial line from each 
patient with NSTI is collected into tubes containing 
EDTA at four time points: on admission and each of the 
following 3 days, always between 08:00 and 14:00 (see 
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table 1). During the first 7 days in the ICU, clinical data 
will be gathered (see table 2). For the orthopaedic control 
group, the blood samples have been drawn at three time 
points: once at baseline (preoperatively), once 2–6 hours 
postoperatively and once on the day after surgery 
between 08:00 and 12:00. For both patient groups, the 
anticoagulated blood is put on ice until centrifugation 
(within 40 min of collection, at 3500 rpm for 10 min). The 
supernatant (serum) is stored in 1 mL vials at −80°C until 
analysis.
data analysis
Studies I, II and III: routine blood analysis
These tests will be run at the Department of Clinical 
Biochemistry, Copenhagen University Hospital. Among 
others: platelets, pH, base excess, fibrinogen, Interna-
tional Normalized Ratio (INR), D-dimer, C-Reactive 
Protein (CRP), procalcitonin, lactate, bilirubin, potas-
sium, sodium, calcium, glucose, creatinine, haemoglobin, 
leucocytes.
Studies I and II: sTM, syndecan-1, sE-Selectin, VE-cadherin and 
protein C levels
These tests will be conducted at the Department of Clin-
ical Immunology, Copenhagen University Hospital. All the 
biomarkers will be measured using ELISA methods from 
various companies (Nordic Biosite for sTM, syndecan-1 
and sE-Selectin; R&D systems for VE-cadherin; Orion 
Diagnostica for protein C).
Study III: suPAR levels
These tests will be conducted at the Clinical Research 
Department, Hvidovre Hospital. suPAR levels will be 
measured using ELISA from ViroGates. Using a double 
monoclonal antibody sandwich ELISA assay, samples and 
peroxidase-conjugated anti-suPAR are mixed together. 
Incubation is done in anti-suPAR precoated micro wells. 
Calibration of the recombinant suPAR standards is done 
against healthy human blood donor samples. suPAR 
levels are reported in nanograms per millilitre of plasma.
Hypotheses; primary and secondary outcomes
Study I
Study I hypotheses
1. In patients with NSTI stratified into no sepsis, sepsis 
and septic shock groups as defined by standardised 
criteria,45 HBOTi lowers sTM more than 1.75 ng/mL 
per day.
2. The aforementioned reduction in sTM in patients 
with NSTI after HBOT is statistically significantly 
larger than any reduction in sTM seen in both an 
elective orthopaedic surgery control group and sepsis 
control group.
i HBOT is applied by placing the patient with NSTI inside a HBOT 
chamber, where the patient is continuously breathing 100% O2 through 
a ventilator and endotracheal intubation or if awake through a trans-
parent hood and where the entire chamber is pressurised to 2.8 atmo-
spheres absolute (ATA) for 90 min.
Study I primary outcome
Changes in plasma sTM and syndecan-1 concentrations, 
measured on admission and once daily the first 3 days in 
the ICU.
Study I secondary endpoint
A subanalysis of the differences in the aforementioned 
endothelial biomarkers between patients with NSTI who 
do not receive HBOT within the first 24 hours of ICU 
admission (because they are deemed too unstable for 
HBOT) versus those who receive HBOT within the first 
12 and 24 hours of ICU admission.
Study II
Study II hypothesis
1. Inpatients with NSTI stratified into no sepsis, sepsis 
and septic shock groups as defined by standardised 
criteria,45 HBOTi lowers sE-selectin more than 1.1 ng/
mL per day.
2. The aforementioned reduction in sE-selectin 
in patients with NSTI after HBOT is statistically 
significantly larger than any reduction in sE-selectin 
seen in both an elective orthopaedic surgery control 
group and sepsis control group.
Study II primary endpoint
Changes in plasma sE-selectin, VE-cadherin and protein 
C concentrations, measured on admission and once daily 
the first 3 days in the ICU.
Study II secondary endpoint
A subanalysis of the differences in the aforementioned 
biomarkers between patients with NSTI who do not 
receive HBOT within the first 24 hours of ICU admission 
(because they are deemed too unstable for HBOT) versus 
those who receive HBOT within the first 12 and 24 hours 
of ICU admission.
Study III
Study III hypotheses
Inpatients with NSTI stratified into no sepsis, sepsis and 
septic shock groups as defined by standardised criteria,45 
suPAR levels are a predictor for mortality.
Inpatients with NSTI stratified into no sepsis, sepsis and 
septic shock groups as defined by standardised criteria,45 
suPAR levels reflect patients with NSTI’ clinical condition 
as assessed by Simplified Acute Physiology Score II (SAPS 
II) and Sequential Organ Failure Assessment (SOFA) 
scores.
Study III primary endpoint
Association between plasma suPAR levels, measured on 
admission and once daily during the first 3 days in the 
ICU, and NSTI mortality, SAPS II and SOFA scores.
Joint secondary endpoints for studies I, II and III
In studies I, II and III, the following outcomes will be 
analysed for the NSTI group only:
 ► Mortality in the ICU and at 30, 90 and 180 days
group.bmj.com on November 27, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Polzik P, et al. BMJ Open 2017;7:e017805. doi:10.1136/bmjopen-2017-017805
Open Access
 ► Amputations.
The following characteristics are registered in the 
INFECT database, which we will also be using for our 
studies:
 ► Age and sex
 ► Comorbidities: diabetes mellitus, liver cirrhosis, 
kidney disease, cardiovascular disease, HIV/AIDS, 
hepatitis, intravenous drug use, malignancy
 ► Body mass index
 ► Mean arterial pressure
 ► Heart rate
 ► Arterial blood gas: partial pressure of oxygen, partial 
pressure of carbon dioxide, HCO3, base excess, pH
 ► Standard biochemistry: K+, Na+, Ca2+, glucose, creati-
nine, haemoglobin etc
 ► Norepinephrine use
 ► Mechanical ventilation
 ► ICU scores: SAPS II, SOFA without Glasgow Coma 
Scale (GCS), Laboratory Risk Indicator for Necrotising 
Fasciitis
 ► Primary infectious focus
 ► Primary symptoms: pain, erythema, tachycardia, fever
 ► Pathogen type
 ► Time between admittance at primary hospital to the 
first surgery
 ► Definitive treatment at Copenhagen University 
Hospital: antibiotics, immunoglobulin and HBOT
 ► Treatment at primary hospital: antibiotics, immuno-
globulin, surgical treatment
 ► Immunocompromising drugs prior to admission.
sample size
Study I
The test kits we will be using to measure our primary 
outcome sTM (Human sCD141 ELISA kit, Nordic 
Biosite) have an interassay standard variation of 0.58 ng/
mL. In order to be certain that measured changes in sTM 
concentration are not a result of interassay SD, we have set 
our minimum relevant difference in sTM to three times 
the interassay standard variation, thus 1.75 ng/mL.
We prepared a power calculation using a Wilcoxon 
rank-sum test. Assuming an estimated SD of 4.6 ng/mL 
and a mean of 9.9 ng/mL,12 we will need to include a 
maximum of 150 patients with NSTI and 50 elective 
surgery patients to reach a statistical power of at the very 
least 60% (a very conservative estimate) and presumably 
closer to 85% (more realistic estimate) at a 5% signifi-
cance level. The estimates depend on data distribution.
Study II
The test kits we will be using to measure our primary 
outcome sE-selectin (Human CD62E ELISA kit, Diaclone) 
have an interassay standard variation of 0.37 ng/mL. In 
order to be certain that measured changes in sE-selectin 
concentration are not a result of interassay standard vari-
ation, we have set our minimum relevant difference in 
sE-selectin to three times the interassay standard varia-
tion, thus 1.1 ng/mL.
Assuming an estimated SD of 209 ng/mL (septic shock) 
vs 23 ng/mL (severe sepsis and sepsis) and means of 295 vs 
181 ng/mL, respectively,46 we will need to include at least 
132 patients with NSTI and 50 elective surgery patients to 
reach a statistical power of 90% at a 5% significance level.
Study III
suPAR levels during NSTI have never previously been 
examined. In order to estimate sample size and since 
most patients with NSTI are also septic, we are basing our 
sample size calculation on a previous study concerning 
the correlation between suPAR and sepsis.29 This study 
found statistically significant correlation between suPAR 
levels and mortality in 141 patients. This is also our goal. 
Further studies have also found significant correlations 
between suPAR, sepsis and mortality in 132 patients.30 We 
will include at least 150 patients with NSTI during this 
study.
statistical considerations
Studies I and II
To check whether the HBOT treatment has an effect on 
the range of biomarkers, we will analyse the means and 
variances of the biomarkers in the NSTI group and the 
two control groups, the orthopaedic patients and the 
patients with sepsis. Non-parametric data will be log-trans-
formed and will be presented as median values with IQR. 
Wilcoxon rank-sum tests will be used for group compari-
sons. Fisher’s exact test will be used for categorical data. 
Correlation analysis will be performed using Spearman 
rank correlation or Pearson correlation.
Study III
To assess the quality of suPAR as a predictor of health 
outcomes, a model selection exercise will be conducted 
with various types of regression models. The type of 
regression will vary with the type of health-outcome, with 
suPAR as the predictor in all cases. Non-parametric data 
will be log-transformed and will be presented as median 
values with IQR. Fisher’s exact test will be used for cate-
gorical data. Receiver operating characteristic curve anal-
ysis will be applied to determine suPARs accuracy as a 
marker of severity and mortality in patients with NSTI. We 
will construct Kaplan-Meier curves for survival data. Statis-
tically significant results are when p<0.05. Corrections 
for multiple comparisons will be done using Wilcoxon 
rank-sum tests.
EtHIcs And dIssEMInAtIon
The study will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki. The Regional Health 
Research Ethics Committee and the Danish Data Protection 
Agency (responsible for the correct processing of confiden-
tial patient data) have approved the study (RHREC docu-
ment number: H-16021845; DDPA j. no.: RH-2016–199). 
The investigator will inform the Research Ethics Committee 
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and the Danish Data Protection Agency of any significant 
changes to the protocol.
Written informed consent will be acquired from either 
the patients themselves or their next of kin as well as from 
their primary healthcare physician, as required by Danish 
law. This study itself poses no additional risk to the patients, 
as patients will receive standard NSTI treatment at Copen-
hagen University Hospital, in no way different from the 
usual treatment. To maintain confidentiality, each patient is 
assigned a pseudonymous research code. Access to patient 
data analysis is restricted to the investigators.
The study has been registered at the international data-
base of clinical trials (www. clinicaltrials. gov; NCT03147352).
Results will be disseminated at national and international 
conferences and then published in international peer-re-
viewed scientific journals. Positive, negative and any incon-
clusive results will be published. The advanced knowledge of 
NSTIs generated by the above studies will be used to create 
evidence-based guidelines for classification and manage-
ment. Through the INFECT project, we have access to the 
UK NSTI patient organisation together with the NSTI clin-
ical consortium. This provides excellent means for efficient 
dissemination of guidelines and other advances made in 
the project to relevant end-users, including medical staff, 
patients and their relatives, small and medium enterprises 
and researchers.
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